LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article: Feasibility and Efficacy of Craniosacral Therapy on Sleep Quality in Fibromyalgia Syndrome: a Pre-Post Pilot Trial.

Ughreja, Reepa Avichal / Venkatesan, Prem / Gopalakrishna, Dharmanand Balebail / Singh, Yogesh Preet

International journal of therapeutic massage & bodywork

2023 Volume 16, Issue 2, Page(s) 4–11

Abstract: Background: Sleep disturbance is one of the key symptoms of fibromyalgia syndrome (FMS), which negatively affects the participants' quality of life. Craniosacral therapy (CST) is a gentle manual technique found to have significant effects on pain and ... ...

Abstract	Background: Sleep disturbance is one of the key symptoms of fibromyalgia syndrome (FMS), which negatively affects the participants' quality of life. Craniosacral therapy (CST) is a gentle manual technique found to have significant effects on pain and function in chronic pain participants. However, limited evidence exists on its effectiveness on sleep quality in FMS participants. Purpose: To evaluate the feasibility and effectiveness of CST on sleep quality in FMS participants. Setting: Outpatient physiotherapy department of a hospital in Bangalore. Participants: Participants diagnosed with FMS. Research design: A pre/post pilot trial. Intervention: Once weekly, 45-minute sessions of CST for 12 weeks. The participants continued the standard medical care prescribed by the physician. Main outcome measure: The sleep quality was evaluated using Pittsburgh Sleep Quality Index (PSQI) at baseline and 12 weeks. The data analysis was carried out using paired Results: 9 out of 10 included participants completed the treatment and were included for analysis. The results of the paired t test showed significant improvement in the global PSQI score ( Conclusion: CST was feasible to deliver with high retention, acceptability, and minimal adverse events. It significantly improved sleep quality in FMS participants along with standard medical care. However, future studies with larger sample sizes and appropriate control groups are required to confirm the findings.
Language	English
Publishing date	2023-06-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2452024-X
ISSN	1916-257X
ISSN	1916-257X
DOI	10.3822/ijtmb.v16i2.819
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder.

Singh, Yogesh Preet / Roy, Debaditya / Jois, Bhargavi / Shetti, Mohit

BMJ case reports

2022 Volume 15, Issue 4

Abstract: A man in his 60s developed reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin (iBCG) for papillary carcinoma of bladder. Evaluation revealed leucocytosis and raised inflammatory markers. HLA B27 was positive. Based on the ... ...

Abstract	A man in his 60s developed reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin (iBCG) for papillary carcinoma of bladder. Evaluation revealed leucocytosis and raised inflammatory markers. HLA B27 was positive. Based on the temporal relationship, it was attributed to BCG-related reactive arthritis. iBCG was stopped. Treatment with non-steroidal anti-inflammatory drugs (NSAIDS) and glucocorticoids were ineffective. Prolonged course of disease-modifying antirheumatic drugs (DMARDS) was required which aided in alleviation of symptoms and sustained remission. Intravesical BCG therapy is a treatment for bladder cancer. It is rarely associated with reactive arthritis, which responds to discontinuation of iBCG and treatment with NSAIDS and/or short-term glucocorticoids. iBCG-related reactive arthritis commonly has an acute/subacute course. Chronic arthritis as observed in our case requiring prolonged treatment with DMARDS is rare.
MeSH term(s)	Administration, Intravesical ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Reactive/chemically induced ; Arthritis, Reactive/diagnosis ; Arthritis, Reactive/drug therapy ; BCG Vaccine/adverse effects ; Carcinoma, Papillary/drug therapy ; Female ; Glucocorticoids/therapeutic use ; Humans ; Male ; Mycobacterium bovis ; Urinary Bladder/pathology ; Urinary Bladder Neoplasms/pathology
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Antirheumatic Agents ; BCG Vaccine ; Glucocorticoids
Language	English
Publishing date	2022-04-13
Publishing country	England
Document type	Case Reports ; Journal Article
ISSN	1757-790X
ISSN (online)	1757-790X
DOI	10.1136/bcr-2022-249208
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Effectiveness of myofascial release on pain, sleep, and quality of life in patients with fibromyalgia syndrome: A systematic review.

Ughreja, Reepa Avichal / Venkatesan, Prem / Balebail Gopalakrishna, Dharmanand / Singh, Yogesh Preet

Complementary therapies in clinical practice

2021 Volume 45, Page(s) 101477

Abstract: Background and purpose: There is limited evidence on the effects of myofascial release on fibromyalgia symptoms. This review aims to update the evidence on the effectiveness of myofascial release on pain, sleep, and quality of life in patients with ... ...

Abstract	Background and purpose: There is limited evidence on the effects of myofascial release on fibromyalgia symptoms. This review aims to update the evidence on the effectiveness of myofascial release on pain, sleep, and quality of life in patients with fibromyalgia syndrome. Methods: The review was prepared following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Scopus, Cochrane Library, Physiotherapy Evidence Database, Embase, Web of Science, Cumulative Index to Nursing and Allied Health Literature Complete, and ProQuest Medical library were searched from their inception to April 1, 2021 for randomized or nonrandomized clinical trials published in English. Studies consisting of myofascial release alone or in combination with exercise as the intervention were included. The quality of the studies was evaluated using Cochrane Risk of Bias 2.0. Results: Six studies, including a total of 279 participants, were included in the review. The meta-analysis showed a large significant effect of myofascial release on pain posttreatment (-0.81[95% CI = -1.15 to -0.47], p < 0.00001) and a moderate effect at 6 months post-treatment (-0.61, 95% CI = -0.95 to -0.28, p = 0.0003). Conclusion: The review demonstrated moderate evidence for the effect of therapist administered and self-myofascial release in improving pain, sleep subscales, and quality of life against sham and no treatment, respectively, in fibromyalgia syndrome patients. However, more high-quality randomized controlled trials with manual control group are required to be conducted at different geographical locations to generalize the findings.
MeSH term(s)	Fibromyalgia/therapy ; Humans ; Manipulation, Osteopathic ; Pain ; Quality of Life ; Sleep
Language	English
Publishing date	2021-08-27
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Review ; Systematic Review
ZDB-ID	2182834-9
ISSN	1873-6947 ; 1744-3881
ISSN (online)	1873-6947
ISSN	1744-3881
DOI	10.1016/j.ctcp.2021.101477
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4912: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Polyarteritis nodosa: resolution of radiological changes.

Jain, Naman / Shankar, Balasubramanyam / Mitra, Somnath / Singh, Yogesh Preet

Rheumatology (Oxford, England)

2020 Volume 60, Issue 7, Page(s) 3481–3482

MeSH term(s)	Adult ; Azathioprine/therapeutic use ; Celiac Artery/diagnostic imaging ; Cyclophosphamide/therapeutic use ; Glucocorticoids/therapeutic use ; Humans ; Imaging, Three-Dimensional ; Immunosuppressive Agents/therapeutic use ; Male ; Methylprednisolone/therapeutic use ; Polyarteritis Nodosa/diagnostic imaging ; Polyarteritis Nodosa/drug therapy ; Tomography, X-Ray Computed ; Treatment Outcome
Chemical Substances	Glucocorticoids ; Immunosuppressive Agents ; Cyclophosphamide (8N3DW7272P) ; Azathioprine (MRK240IY2L) ; Methylprednisolone (X4W7ZR7023)
Language	English
Publishing date	2020-12-05
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/keaa734
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A modified juvenile arthritis damage index to improve articular damage assessment in juvenile idiopathic arthritis--enthesitis-related arthritis (JIA-ERA).

Singh, Yogesh Preet / Aggarwal, Amita

Clinical rheumatology

2012 Volume 31, Issue 5, Page(s) 767–774

Abstract: Juvenile arthritis damage index (JADI) consists of two parts which measure articular (JADI-A) and extra-articular (JADI-E) damage in patients with juvenile idiopathic arthritis (JIA). It does not include assessment of cardiac dysfunction and joint areas ... ...

Abstract	Juvenile arthritis damage index (JADI) consists of two parts which measure articular (JADI-A) and extra-articular (JADI-E) damage in patients with juvenile idiopathic arthritis (JIA). It does not include assessment of cardiac dysfunction and joint areas commonly affected in enthesitis-related arthritis (ERA) category of JIA. We have tried to study if modification of JADI will improve its performance in JIA-ERA. We studied 101 consecutive patients of JIA-ERA. JADI-A was modified (JADI-AM) to include damage assessment of tarsal joints and lumbar spine. JADI-E was modified (JADI-EM) to include assessment of symptomatic cardiac dysfunction. The performances of the modified and standard JADI were compared. Ninety-seven patients were male. The median age was 18 years (9-36). At a median disease duration of 6 years (1-24), joint damage was observed in 47 as assessed by JADI-A. JADI-AM could identify 11 more patients (N = 58) with articular damage. JADI-AM had good correlation with number of joints with limitation of movement (Spearman's [rS] = 0.9) and low to moderate correlation (rS < 0.7) with measures of disease activity and functional status. JADI-AM discriminated well among patients with different disability levels. Extra-articular damage was observed in 35, and modification of JADI-E with inclusion of cardiac dysfunction did not identify any additional patient. Thus, we propose a modification of the JADI-A (JADI-AM). In JIA-ERA, modification of JADI-A improves its ability to identify articular damage. Modification of the JADI-E may not be needed as symptomatic cardiac involvement is rare.
MeSH term(s)	Adolescent ; Adult ; Arthritis, Juvenile/complications ; Arthritis, Juvenile/pathology ; Arthritis, Juvenile/physiopathology ; Child ; Cross-Sectional Studies ; Disability Evaluation ; Female ; Heart Diseases/complications ; Heart Diseases/diagnosis ; Heart Diseases/physiopathology ; Heart Function Tests ; Humans ; Joints/pathology ; Joints/physiopathology ; Lumbar Vertebrae/pathology ; Lumbar Vertebrae/physiopathology ; Male ; Severity of Illness Index ; Tarsal Joints/pathology ; Tarsal Joints/physiopathology ; Young Adult
Language	English
Publishing date	2012-01-11
Publishing country	Germany
Document type	Journal Article
ZDB-ID	604755-5
ISSN	1434-9949 ; 0770-3198
ISSN (online)	1434-9949
ISSN	0770-3198
DOI	10.1007/s10067-011-1928-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1740: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Risk factors associated with COVID-19 in systemic lupus erythematosus: Results from a longitudinal prospective cohort.

Lupus

2023 Volume 32, Issue 4, Page(s) 560–564

Abstract: Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.: Methods: ...

Abstract	Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome. Methods: We conducted a longitudinal prospective study across 15 rheumatology centres during the first wave of the pandemic to understand the risk factors contributing to COVID-19 in SLE patients. During the 6 months follow-up, those who tested positive for COVID-19, their clinical course and outcome information were recorded. Results: Through the study period (April-December 2020), 36/1379 lupus patients (2.9%) developed COVID-19. On analysing the COVID-19 positive versus negative cohort during the study period, male gender (adjusted RR 3.72, 95% C.I. 1.85,7.51) and diabetes (adjusted RR 2.94, 95% C.I. 1.28, 6.79) emerged as the strongest risk factors for COVID-19, in the adjusted analysis. There was no significant influence of organ involvement, hydroxychloroquine, glucocorticoid dosage (prednisolone< 7.5 mg or ≥ 7.5 mg/day) or IS on the risk of COVID-19. There was only one death (1/36) among the lupus patients due to COVID-19. Conclusion: Traditional risk factors rather than lupus disease process or IS influenced the risk of COVID-19 in our cohort.
MeSH term(s)	Humans ; Male ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Prospective Studies ; COVID-19/complications ; Longitudinal Studies ; Immunosuppressive Agents/adverse effects ; Risk Factors
Chemical Substances	Immunosuppressive Agents
Language	English
Publishing date	2023-02-02
Publishing country	England
Document type	Journal Article
ZDB-ID	1154407-7
ISSN	1477-0962 ; 0961-2033
ISSN (online)	1477-0962
ISSN	0961-2033
DOI	10.1177/09612033231155837
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3717: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases.

BMC rheumatology

2022 Volume 6, Issue 1, Page(s) 32

Abstract: Background: We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).!## ...

Abstract	Background: We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs). Methods: This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome. Results: COVID-19 occurred in 314 (3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129, 219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoids in moderate dose (7.5-20 mg/day) conferred higher risk (RR = 1.72) of infection. Among the IS, Mycophenolate mofetil (MMF), Cyclophosphamide (CYC) and Rituximab (RTX) use was higher in patients with COVID 19. However, the conventional risk factors such as male sex (RR = 1.51), coexistent diabetes mellitus (RR = 1.64), pre-existing lung disease (RR = 2.01) and smoking (RR = 3.32) were the major contributing risk factors for COVID-19. Thirteen patients (4.14%) died, the strongest risk factor being pre-existing lung disease (RR = 6.36, p = 0.01). Incidence (17.5 vs 5.3 per 1 lakh (Karnataka) and 25.3 vs 7.9 per 1 lakh (Kerala)) and case fatality (4.1% vs 1.3% (Karnataka) and 4.3% vs 0.4% (Kerala)) rate of COVID-19 was significantly higher (p < 0.001) compared to the general population of the corresponding geographic region. Conclusions: Immunosuppressants have a differential impact on the risk of COVID-19 occurrence in AIRD patients. Older age, males, smokers, hypertensive, diabetic and underlying lung disease contributed to higher risk. The incidence rate and the case fatality rate in AIRD patients is much higher than that in the general population.
Language	English
Publishing date	2022-06-14
Publishing country	England
Document type	Journal Article
ZDB-ID	2918121-5
ISSN	2520-1026 ; 2520-1026
ISSN (online)	2520-1026
ISSN	2520-1026
DOI	10.1186/s41927-022-00264-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Central nervous system tuberculosis: mimicking neuropsychiatric systemic lupus erythematosus.

Dhir, Varun / Singh, Yogesh Preet / Misra, Ramnath / Aggarwal, Amita

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2012 Volume 18, Issue 2, Page(s) 113–114

MeSH term(s)	Adult ; Antitubercular Agents/administration & dosage ; Diagnosis, Differential ; Diagnostic Errors/prevention & control ; Humans ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/diagnosis ; Lupus Erythematosus, Systemic/drug therapy ; Magnetic Resonance Imaging/methods ; Male ; Prednisolone/administration & dosage ; Prednisolone/adverse effects ; Tomography, X-Ray Computed/methods ; Treatment Outcome ; Tuberculoma, Intracranial/diagnosis ; Tuberculoma, Intracranial/drug therapy ; Tuberculoma, Intracranial/etiology ; Tuberculoma, Intracranial/physiopathology ; Tuberculosis, Central Nervous System/diagnosis ; Tuberculosis, Central Nervous System/drug therapy ; Tuberculosis, Central Nervous System/etiology ; Tuberculosis, Central Nervous System/physiopathology ; Tuberculosis, Pulmonary/diagnosis ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/etiology ; Tuberculosis, Pulmonary/physiopathology
Chemical Substances	Antitubercular Agents ; Prednisolone (9PHQ9Y1OLM)
Language	English
Publishing date	2012-03
Publishing country	United States
Document type	Case Reports ; Letter
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0b013e31824d2a97
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.

Myles, Arpita / Viswanath, Vishad / Singh, Yogesh Preet / Aggarwal, Amita

The Journal of rheumatology

2011 Volume 38, Issue 9, Page(s) 1994–1999

Abstract: Objective: Membrane-bound receptor for advanced glycation endproducts (mRAGE) is overexpressed in response to increasing concentrations of its ligand (e.g., S100A12) and triggers an inflammatory immune response. In contrast, soluble RAGE (sRAGE) acts as ...

Abstract	Objective: Membrane-bound receptor for advanced glycation endproducts (mRAGE) is overexpressed in response to increasing concentrations of its ligand (e.g., S100A12) and triggers an inflammatory immune response. In contrast, soluble RAGE (sRAGE) acts as a decoy receptor and downmodulates inflammation. Decreased sRAGE levels are associated with autoimmune diseases; however, limited data are available in juvenile idiopathic arthritis (JIA). We studied sRAGE levels in patients with JIA [enthesitis-related arthritis (ERA) category]. Methods: sRAGE levels were estimated in the serum of patients with ERA JIA (n = 101), systemic-onset JIA and polyarticular JIA (n = 10 each), and healthy controls (n = 45). Synovial fluid (SF) sRAGE was measured in patients with ERA, rheumatoid arthritis, reactive arthritis, and osteoarthritis (n = 10). Levels of S100A12 were also measured. Twenty-four patients with ERA were followed for 4 months. Disease activity was assessed by swollen joint count (SJC), tender joint count (TJC), and erythrocyte sedimentation rate (ESR). All levels are expressed as median (range). Results: The serum sRAGE (pg/ml) level was significantly lower in patients compared to healthy controls [515 (64-1887) vs 1542 (627-3159); p < 0.0001]. In paired samples, SF had lower levels compared to corresponding plasma level [102 (51-799) vs 481 (134-1006); p < 0.0001]. The level of S100A12 (ng/ml) was higher in SF (1042; 573-1415) than serum (638; 208-779). Serum sRAGE correlated negatively with S100A12 levels (r = -0.474; p < 0.01.), ESR (r = -0.306; p < 0.01), and SJC (r = -0.237; p < 0.05), but not with TJC (r = -0.134; p = NS). The levels of sRAGE remained stable over time in patients with stable disease. Conclusion: Levels of sRAGE are reduced in patients with ERA and correlate negatively with disease activity and S100A12 levels. sRAGE may be a modulator of inflammation in these patients.
MeSH term(s)	Adolescent ; Arthritis, Juvenile/blood ; Arthritis, Juvenile/immunology ; Arthritis, Juvenile/pathology ; Child ; Child, Preschool ; Down-Regulation/immunology ; Female ; Humans ; Infant ; Inflammation Mediators/antagonists & inhibitors ; Inflammation Mediators/blood ; Inflammation Mediators/physiology ; Male ; Predictive Value of Tests ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/blood ; Receptors, Immunologic/physiology ; S100 Proteins/blood ; S100A12 Protein ; Severity of Illness Index ; Synovial Fluid/immunology ; Synovial Fluid/metabolism ; Young Adult
Chemical Substances	Inflammation Mediators ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic ; S100 Proteins ; S100A12 Protein ; S100A12 protein, human
Language	English
Publishing date	2011-09
Publishing country	Canada
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	194928-7
ISSN	1499-2752 ; 0315-162X
ISSN (online)	1499-2752
ISSN	0315-162X
DOI	10.3899/jrheum.110058
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 135: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Evidence of cellular immune response to outer membrane protein of Salmonella typhimurium in patients with enthesitis-related arthritis subtype of juvenile idiopathic arthritis.

Singh, Yogesh Preet / Singh, Amit Kumar / Aggarwal, Amita / Misra, Ramnath

The Journal of rheumatology

2011 Volume 38, Issue 1, Page(s) 161–166

Abstract: Objective: enthesitis-related arthritis subtype of juvenile idiopathic arthritis (JIA-ERA) clinically resembles reactive arthritis (ReA). In patients with ReA the immune response is targeted at the outer membrane protein (OMP) of Salmonella typhimurium. ...

Abstract	Objective: enthesitis-related arthritis subtype of juvenile idiopathic arthritis (JIA-ERA) clinically resembles reactive arthritis (ReA). In patients with ReA the immune response is targeted at the outer membrane protein (OMP) of Salmonella typhimurium. We studied the immune response in JIA-ERA to S. typhimurium OMP. Methods: synovial fluid mononuclear cells (SFMC) and peripheral blood mononuclear cells (PBMC) were isolated from blood and SF of patients with JIA-ERA. Lymphocyte transformation test was done with S. typhimurium OMP and crude bacterial lysates of Yersinia enterocolitica, Shigella flexneri, and S. typhimurium. IgG and IgA ELISA were performed in serum and SF using S. typhimurium OMP as antigen and compared with sera from healthy controls. Results: in PBMC samples (n = 25) an antigen-specific proliferative response was seen in 13 patients and a cross-reactive response in 6. Among these 19 patients, 12 showed response to OMP. In SFMC (n = 15) antigen-specific responses were seen in 3 patients and cross-reactive responses in 9. Among these 12 patients, 11 showed response to OMP. The IgG and IgA anti-OMP antibody concentrations in serum and SF were similar in patients and controls. Conclusion: in JIA-ERA, OMP is the major antigenic target recognized by both SFMC and PBMC. Response to OMP is independent of specific bacterial response, suggesting that OMP is the immunodominant antigen. In these patients, absence of significant humoral response suggests response to OMP is mainly T cell mediated.
MeSH term(s)	Adolescent ; Arthritis, Juvenile/immunology ; Arthritis, Juvenile/microbiology ; Arthritis, Reactive/immunology ; Arthritis, Reactive/microbiology ; Bacterial Outer Membrane Proteins/immunology ; Humans ; Leukocytes, Mononuclear/cytology ; Leukocytes, Mononuclear/immunology ; Lymphocyte Activation ; Male ; Salmonella typhimurium/immunology ; Synovial Fluid/cytology ; Young Adult
Chemical Substances	Bacterial Outer Membrane Proteins
Language	English
Publishing date	2011-01
Publishing country	Canada
Document type	Journal Article
ZDB-ID	194928-7
ISSN	1499-2752 ; 0315-162X
ISSN (online)	1499-2752
ISSN	0315-162X
DOI	10.3899/jrheum.100542
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 135: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito